Navigation Links
Hide and seek signals
Date:12/15/2011

The white blood cells that fight disease and help our bodies heal are directed to sites of infection or injury by 'exit signs' chemical signals that tell them where to pass through the blood vessel walls and into the underlying tissue. New research at the Weizmann Institute, which appeared in Nature Immunology online, shows how the cells lining blood vessel walls may act as 'selectors' by hiding the signals where only certain 'educated' white blood cells will find them.

In previous studies, Prof. Ronen Alon and his team in the Immunology Department had found that near sites of inflammation, white blood cells rapidly crawl along the inner lining of the blood vessels with tens of tiny legs that grip the surface tightly, feeling for the exit sign. Such signs consist of migration-promoting molecules called chemokines, which the cells lining the blood vessels endothelial cells display on their outer surfaces like flashing lights.

In the new study, Alon and his team, including Drs. Ziv Shulman and Shmuel Cohen, found that not all chemokine signals produced by endothelial cells are on display. They observed the recruitment of subsets of immune cells called effector cells that are the 'special forces' of the immune system: They receive training in the lymph nodes, where they learn to identify a particular newly-invading pathogen and then return to the bloodstream on a search and destroy mission. Like the other white blood cells, effector cells crawled on tiny appendages along the lining of inflamed blood vessels near the site of pathogen entry, but rather than sensing surface chemokines, they used their legs to reach into the endothelial cells in search of the migration-promoting chemokines.

As opposed to the external exit signs, these chemokines were held in tiny containers vesicles inside the inflamed endothelial cell walls. The effector cells paused in the joins where several cells met, inserting their legs through the walls of several endothelial cells at once to trap chemokines as they were released from vesicles at the endothelial cell membrane. Once they obtained the right chemokine directives, the immune cells were quickly ushered out through the blood vessel walls toward their final destination.

The researchers think that keeping the chemokines inside the endothelial cells ensures, on the one hand, that these vital signals will be safe from getting washed away in the blood or eaten by various enzymes. On the other hand, it guarantees that only those effector cells with special training that can make the extra effort to find the signals will pass through.

Alon: 'We are now seeing that the blood vessel endothelium is much more than just a passive, sticky barrier it actively selects which recruited cells actually cross the barrier and which will not. The endothelial cells seem to play an active role in showing the immune cells the right way out, though we're not sure exactly how. Moreover, we think that tumors near blood vessels might exploit these trafficking rules for their benefit by putting the endothelial cells in a quiescent state or making the endothelium produce the 'wrong' chemokines. Thus, immune cells capable of destroying these tumors will not be able to exit the blood and navigate to the tumor site, while other immune cells that aid in cancer growth will.'


'/>"/>
Contact: Yivsam Azgad
news@weizmann.ac.il
972-893-43856
Weizmann Institute of Science
Source:Eurekalert

Related medicine news :

1. Epigenetic signals differ across alleles
2. Higher anxiety, depression among women may have basis in cell signals
3. Neuro signals study gives new insight into brain disorders
4. Effects of exercise on meal-related gut hormone signals
5. Atomic structure discovered for a sodium channel that generates electrical signals in living cells
6. Researchers discover that changes in bioelectric signals cause tadpoles to grow eyes in back, tail
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... EDWARDSVILLE, Ill. (PRWEB) , ... ... ... University Edwardsville School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and ... educated healthcare professionals on guideline updates for the primary prevention of cardiovascular ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of ... collection of specialty vendors and unique items from across the nation, this holiday-themed event ... wellness services offered by the VNA. The boutique will be open Saturday, November ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... healthcare compliance program management, will showcase a range of technology and learning solutions ... Living (NCAL) Convention and Expo to be held October 14–18, 2017 at the ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one ... an innovative new design of the shoulder pad. The shoulder pad provides optimal ... controlling your pain while using cold therapy. By utilizing ice and water that is ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology: